Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Assets Average (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Assets Average for 9 consecutive years, with $909.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average changed N/A to $909.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $909.1 million, a N/A change, with the full-year FY2025 number at $911.8 million, up 7.86% from a year prior.
  • Assets Average was $909.1 million for Q4 2025 at Iovance Biotherapeutics, roughly flat from $906.2 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $938.6 million in Q1 2025 to a low of $610.3 million in Q1 2023.
  • A 3-year average of $837.6 million and a median of $825.1 million in 2024 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: soared 35.2% in 2024, then rose 13.76% in 2025.
  • Iovance Biotherapeutics' Assets Average stood at $816.3 million in 2023, then grew by 1.07% to $825.1 million in 2024, then increased by 10.18% to $909.1 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Assets Average are $909.1 million (Q4 2025), $906.2 million (Q3 2025), and $937.1 million (Q2 2025).